Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIMSON: BI 764524 in moderately severe to severe non-proliferative diabetic retinopathy
jRCT2071240025Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of BI 764524 in nonproliferative diabetic retinopathy (NPDR) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: >=2-step improvement in DRSS at Week 52. Started Oct 2024; status: active, not recruiting.
02
Drugs
BI 764524
03
Conditions
nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on jRCT2071240025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240025.